Navigation Links
Defensins neutralize anthrax toxin

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers. Their findings demonstrate a new mechanism by which EBV transforms human B cells from the immune system into cancerous cells, which can lead to development of B-cell lymphomas.

Erle S. Robertson, PhD, Associate Professor of Microbiology and Director of Tumor Virology, with Penn's Abramson Cancer Center and MD/PhD student Jason Knight, published their results in the early March issue of Molecular and Cellular Biology.

Using human cell cultures infected with the Epstein-Barr virus, the investigators found that a specific viral protein targets a molecule that normally regulates the cell-cycle progression, or duplication process, of resting B cells. In the presence of this viral protein ?called EBNA3C (for EBV nuclear antigen) ?the cell cycle of the usually quiescent human B cells gets a jump start, which ultimately initiates uncontrolled growth.

EBV, a member of the herpesvirus family and one of the most common human viruses, plays a role in cancers such as lymphoproliferative diseases in transplant or AIDS patients, Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma, and also causes the well-known disease, infectious mononucleosis. As many as 95 percent of adults 20 years and older have been infected with EBV, but show no symptoms.

"Viruses that are associated with cancers typically target the cell cycle to gain control," says Robertson. "However, this is the first time that laboratory research into how EBV drives the cancer process has directly identified a critical component of the cell cycle for control. Now we can develop targeted therapeutics to disrupt the function of this viral protein." The researchers surmise that the first use of future therapies from these studies will be in lymphoprolifera
'"/>

Source:


Page: 1 2

Related biology news :

1. Defensins Ward Off HIV In Two Ways
2. Bleach found to neutralize mold allergens
3. Scientists seek answers on what activates deadly anthrax spores
4. Antibodies from plants protect against anthrax
5. Critical step traced in anthrax infection
6. US Army plans to bulk-buy anthrax
7. New antibody shows promise as cure for anthrax
8. Effective, safe anthrax vaccine can be grown in tobacco plants
9. UCSD study finds anthrax toxins also harmful to fruit flies
10. Driver of anthrax toxicity could lead to late-stage therapy
11. Scientists design potent anthrax toxin inhibitor

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Defensins neutralize anthrax toxin

(Date:11/25/2009)...NA, Calif.Scientists at the California Institute o...a primitive emotion-like behavior in the fruit fly...hich may be relevant to the relationship between t... hyperactivity disorder (ADHD), are described in t... Drosophila brain contains only about 20,000 neu...
(Date:11/25/2009)...N, WI, NOVEMBER 25, 2009 Soil is the linchpin of ...hydrosphere meet. Despite that, many students see ...othing more. Soil science educators are challenged...recognize the critical importance of soil in the e...cience and earth science teachers at University of...
(Date:11/24/2009)...pus Research Institute (LRI) today named 12 new gr... million, recognize innovative work across a broad... their creativity, novelty, and potential to drive..., and cure the complex disease of systemic lupus. ... lupus researchers across the nation and include i...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3R Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0 15 25 UF 021 4888 1R Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0 15 25 UF 021 4888 2JNCI news brief 3A Melanosome dynamics and sensitivity of melanoma cells to chemotherapy 55208 1Matrixx Initiatives to Webcast 2009 Annual Stockholder Meeting Wednesday August 26 2009 55203 1Matrixx Initiatives to Webcast 2009 Annual Stockholder Meeting Wednesday August 26 2009 55203 2
...eicester researcher has discovered how a protein i...- plays a more vital role than previously understo...ished research has helped to advance medical under...nd heals itself. , The study also reveals that th...entury ago- can also harm internal organs under ce...
...llen a plant produces is closely tied to its sexua...elping explain the evolution of such intimate rela...y one of the first of its kind and published onli...ctional Ecology also helps explain the recent dra...n the shrinking areas of species-rich chalk grassl...
...available in Spanish . , Over the past decades ...r planet have given rise to a growing scientific i.... The fossil fuels that currently dominate our ene...over generating large quantities of contaminating ...scientific community is today devoting great effor...
Other Biology News:New discovery on role of vital protein that fights meningitis 2Ecologists tease out private lives of plants and their pollinators 2More efficient fuel-cells, thanks to a new catalyst 2More efficient fuel-cells, thanks to a new catalyst 3More efficient fuel-cells, thanks to a new catalyst 4
(Date:11/24/2009)... Iceland, November 24 de...d the approval of all of its,"first day" motions b...laware,(the "Bankruptcy Court"). deCODE last week ...r 11 of the United States Bankruptcy Code with the... the Bankruptcy Court allow the company to continu...
(Date:11/24/2009).../PRNewswire-Asia/ -- Shanghai Biolaxy announced th...DA) has approved the,investigational new drug appl...), an innovative insulin formulation to treat diab... its first phase I clinical study. , Diab...ucose and poor,metabolism. The complications of di...
(Date:11/24/2009)...oint has been met for patients with advanced-stage...C CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Z...any"), a global biopharmaceutical company focused ... positive efficacy data from a Phase 2 study with ... (formerly AN-152), in patients with advanced or r...
(Date:11/24/2009)...9 Arena Pharmaceuticals,...company is scheduled to present at the Piper Jaffr...1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. Paci... City. Jack Lief, Arena,s President and Chief Exec... of the company, including its clinical developmen...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
.../PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuti...in Board: BSPM) today reported,financial results f...ighlights for Year Ended December 31, 2008:, --...up from $15.9 million, for 2007., -- Net ... compared to, $3,963,524 in 2007., -- Com...
...el, April 7 InSightec Ltd. announced,today that t...d a label,change for the company,s ExAblate(R) 200... the treatment of women with non-hysteroscopically...ng, the agency allows,physicians to treat up to 10...tion to only treat up to half the fibroid tissue. ...
...wswire-FirstCall/ - Oncolytics Biotech Inc. ("Onco... positive results in its U.K. Phase II clinical tr... of REOLYSIN(R) in combination with low-dose radia...of 16 heavily pretreated patients with advanced ca...ancreas (1), ovarian (1), lung (1), cholangiocarci...
Other Biology Technology:Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 2Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 4Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 5Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 6FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 3
Rabbit Anti-5-HYDROXYTRYPTOPHAN CONJUGATE Polyclonal Antibody, Unconjugated from AbD Serotec
Rabbit Anti-Human IFN-Alpha / Beta R2 (IFNAR2) (CD118) Neutralizing Polyclonal Antibody, Unconjugated from PBL InterferonSource
IMAGEQUANT 100 IQTL from GE Healthcare, formerly Amersham Biosciences
Cathepsin L Fluorometric (cresyl violet) Assay Kit, Magic Red from AbD Serotec
Biology Products: